ALB and breast cancer: These randomized, two-period, crossover, clinical BE studies show that albumin-bound paclitaxel products (QL, HR, and ZDTQ) are bioequivalent to Abraxane® (reference) with a lower intra-cv and similar safety profiles of among Chinese breast cancer patients.